BIOTECH ASSISTANT / FIELD NOTES

Elebsiran–tobevibart meets Phase 3 hepatitis delta endpoint in ECLIPSE 1

Company / institutional announcement · Vir Biotechnology / Business Wire

Source published: 2026-11-08 · Event / reporting date: 2026-11-08

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Vir reported topline results from 124 adults in ECLIPSE 1. The siRNA–antibody combination achieved undetectable HDV RNA plus normal ALT in 44% at Week 48, versus 0% in delayed-treatment controls at Week 12; 79% had undetectable virus. One Grade 3 treatment-related neutrophil decrease occurred. These are company-reported investigational results with different comparison timepoints.

Why it may matter

The findings may inform siRNA–antibody development and filing plans, while complete datasets and further pivotal trials remain important.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oligonucleotide Therapeutics & Delivery

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Alnylam Pharmaceuticals Ionis Pharmaceuticals Wave Life Sciences Arrowhead Pharmaceuticals Silence Therapeutics

Explore field companies →Explore literature →

Related updates

2026-11-08Vir Biotechnology / Business Wire

SOLSTICE update reports prolonged HDV suppression and exploratory treatment-free follow-up

Vir reported undetectable HDV RNA in all 28 SOLSTICE participants completing 96 weeks of elebsiran–tobevibart. Separately, 10 eligible patients stopping treatment achieved sustained viral response at 12 weeks; seven reached 24 weeks and one reached 48 weeks. The exploratory stopping analysis lacks a formal data cut, has incomplete safety follow-up, and does not establish cure.

Oligonucleotide Therapeutics & Delivery Ask AI ↗

2026-11-07Arrowhead Pharmaceuticals

ARO-DIMER-PA shows dual lipid lowering in early human study, with dose-related safety findings

Arrowhead reported Phase 1/2a interim data involving 21 ARO-DIMER-PA recipients and 10 placebo recipients. Across dose cohorts, mean LDL-C fell 26%–65% and median triglycerides fell 56%–78% from baseline; these were not placebo-adjusted effects. Injection-site erythema occurred in 20 treated participants, and one participant receiving 400 mg experienced Grade 3 syncope. Cardiovascular outcome benefit remains unestablished.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-07Cleveland Clinic

Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction

Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗